Brisbane, May 4, 2026, 08:03 AEST
ALS Ltd heads into a two-week countdown to its FY26 results briefing with investors focused on whether the Australian testing group can turn first-half gains in minerals and food testing into a fuller margin recovery. The company has scheduled the briefing for May 18 at 10 a.m. AEST, its investor page showed.
The timing matters because the stock has already had a strong run. ALS shares last traded at A$21.36 on May 1, up 0.38% for the session, with a 52-week range of A$15.97 to A$26.17 and a 24.26% one-year gain.
The near-term test is guidance. ALS in November raised its FY26 organic revenue growth target to 6%-8% from 5%-7%, while saying the profit split should be similar to FY25, with about 48% of underlying net profit after tax in the first half and 52% in the second half. Organic growth means sales growth excluding acquisitions, disposals and currency effects.
The first half set the bar. Underlying revenue rose 13.3% to A$1.66 billion, while underlying EBIT — adjusted operating profit before interest and tax — rose 14.7% to A$287.2 million. The EBIT margin improved 20 basis points to 17.3%; a basis point is one-hundredth of a percentage point.
Chief Executive Malcolm Deane said the half was driven by “strength in Commodities” against weaker Life Sciences conditions. Chairman Nigel Garrard also pointed to “resilient margins” as the board lifted the interim dividend to 19.4 cents a share. ALS Global
ALS is not a pure mining services stock. Reuters describes it as a testing, measurement and inspection firm with two segments, Commodities and Life Sciences; the latter provides testing data for environmental, food, pharmaceutical, electronics, consumer products and animal health clients.
That mix is why the May 18 update carries weight beyond sample volumes. Morningstar says ALS’s expansion into environmental, pharmaceutical and food testing has reduced its earnings exposure to commodities, though commodities have traditionally generated most of its underlying earnings.
But the downside case is still there. ALS said Life Sciences performance was slightly below expectations in the first half, Environmental growth was slower in the Americas, and Pharmaceutical work was hit by a regulatory change in Mexico. It cut FY26 Life Sciences organic growth guidance to 4%-6% from 5%-7%, even as it raised the Commodities target to 12%-14%.
Competitive pressure also sits in the background. In testing, inspection and certification, or TIC, ALS operates alongside larger global names such as SGS, Bureau Veritas and Intertek; Daniel Buerki at Zuercher Kantonalbank told Reuters last year the TIC market was “not very consolidated.” Reuters
Scale remains a live issue. SGS said in February it would keep pursuing acquisitions in 2026 after buying 19 companies in 2025, while ALS said it was assessing bolt-on, or small add-on, acquisition opportunities in key markets and had more than A$550 million of liquidity at Sept. 30.
For ALS investors, May 18 is less about one number than proof that price, volume and lab capacity are moving together. If sample flows ease, Life Sciences drags again, or acquisition spending fails to lift returns, the margin story may get harder to sell.
